| Jaclyn Beth Arabasz, CCC-SLP | |
|
108 High St, Woonsocket, RI 02895-4333 | |
| (401) 767-4600 | |
| Not Available |
| Full Name | Jaclyn Beth Arabasz |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 108 High St, Woonsocket, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215189972 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 6875 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jaclyn Beth Arabasz, CCC-SLP 44 Willis Dr, Cumberland, RI 02864-2066 Ph: (781) 336-6179 | Jaclyn Beth Arabasz, CCC-SLP 108 High St, Woonsocket, RI 02895-4333 Ph: (401) 767-4600 |
News Archive
Robotically steering flexible needles can reach their intended target in tissue with sub-millimetre level accuracy. This has been demonstrated by the doctoral research of Momen Abayazid, who is affiliated with the research institute MIRA of the University of Twente. An major advantage of steering flexible needles is that one can avoid obstacles or sensitive tissues and can re-orient the path of the needle in real time as you insert the needle.
The objective of the research, which was based on the detailed feeding history of almost 900 mothers and babies in the Avon Longitudinal Study of Parents and Children, was to find out whether different feeding patterns and energy intakes provided to infants, affected body weight and BMI later in childhood.
Accium BioSciences, a leading provider of bioanalytical accelerator mass spectrometry (AMS) services in North America, announced today new pricing for its AMS measurement service at $99 per sample. GLP-compliant service is now available at $115 per sample. The new pricing includes sample graphitization and AMS measurement services.
Genentech, a member of the Roche Group today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.
Researchers at the University of Minnesota's Stem Cell Institute have described how an existing genetic tool can be used to study how human embryonic stem cells differentiate.
› Verified 6 days ago
Julia Rei, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 250 Winthrop St, Woonsocket, RI 02895 Phone: 401-767-4850 | |
Lindsay Trottier, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 420 Robinson St, Woonsocket, RI 02895 Phone: 401-767-4765 | |
Holly Carlton, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 192 Avenue A, Woonsocket, RI 02895 Phone: 401-767-4830 | |
Linda Jeanne Cournoyer, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 245 Main Street, Family Resources Community Action, Woonsocket, RI 02895 Phone: 401-766-0900 Fax: 401-766-8737 | |
Ana Maria Ceron, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 245 Main St, Woonsocket, RI 02895 Phone: 401-235-6018 | |
Frances Marie Carty, MA CCCSLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 245 Main St, Woonsocket, RI 02895 Phone: 401-235-6009 Fax: 401-766-8737 |